Surfing the NASH Tsunami

Day Two of TLMdX 2020 - Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint - Ep 35

November 15, 2020 HEP Dynamics LLC Season 1 Episode 35
Surfing the NASH Tsunami
Day Two of TLMdX 2020 - Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint - Ep 35
Chapters
Surfing the NASH Tsunami
Day Two of TLMdX 2020 - Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint - Ep 35
Nov 15, 2020 Season 1 Episode 35
HEP Dynamics LLC


Manal Abdelmalek joins the Surfers to review some of Saturday's most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic.

Manal Abdelmalek joins the Surfers in a free-flowing discussion of Saturday's key papers and posters. Much of the talk focused on Lean NASH -- what it is some of the new diagnostic analyses and algorithms used to identify patients with or at risk of the disease. Stephen talked about the extraordinary path that seladelpar took through its Phase 2 NASH trial and Roger revisited an old podcast question: can Patient-Reported Outcomes be part of clinical development planning and, if so, for what kinds of drugs. Finally, the Surfers welcomed Dr. Nezam Afdhal of Harvard and George Aliphteras of Sonic Incytes in a sponsored extra-sode that is part of the rollout of Velacur, their handheld liver health assessment device. The discussion moved quickly and at the end, all the Surfers were struck powerfully by how dynamically we are learning about this disease.

Show Notes


Manal Abdelmalek joins the Surfers to review some of Saturday's most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic.

Manal Abdelmalek joins the Surfers in a free-flowing discussion of Saturday's key papers and posters. Much of the talk focused on Lean NASH -- what it is some of the new diagnostic analyses and algorithms used to identify patients with or at risk of the disease. Stephen talked about the extraordinary path that seladelpar took through its Phase 2 NASH trial and Roger revisited an old podcast question: can Patient-Reported Outcomes be part of clinical development planning and, if so, for what kinds of drugs. Finally, the Surfers welcomed Dr. Nezam Afdhal of Harvard and George Aliphteras of Sonic Incytes in a sponsored extra-sode that is part of the rollout of Velacur, their handheld liver health assessment device. The discussion moved quickly and at the end, all the Surfers were struck powerfully by how dynamically we are learning about this disease.